For instance, Chen et al. demonstrated that inhibiting GFAT1 sensitizes lung cancer cells to chemotherapy, suggesting the possibility of combining HBP-targeting agents with conventional therapies to enhance treatment outcomes [52]. This evidence concerns the gene GFPT1 and lung cancer.